An increase in the expression of RIPK2 facilitates resistance to innate and adaptive immune therapeutic techniques via pathways such as the IL-6/JAK/STAT3 signaling pathway, the interferon-γ response, and the interferon-α response; thus, RIPK2 plays an important role in gastric cancer [108]. This evidence concerns the gene IL6 and gastric cancer.